Equity Overview
Price & Market Data
Price: $8.75
Daily Change: -$0.11 / 1.26%
Daily Range: $8.65 - $8.77
Market Cap: $151,013,200
Daily Volume: 46,933
Performance Metrics
1 Week: 4.04%
1 Month: 10.90%
3 Months: 2.10%
6 Months: -22.22%
1 Year: 8.02%
YTD: 9.92%
Company Details
Employees: 32
Sector: Health technology
Industry: Biotechnology
Country:
Details
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.